Co-Chairs’ Opening Remarks – A Look Back and a Look Ahead: Examining Key Developments Impacting Life Sciences IP Due Diligence in the Last Year
Henry H. Gu
Vice President, Chief IP Counsel
Akebia Therapeutics, Inc. (Cambridge, MA)
Jennifer K. Gregory
Assistant General Patent Counsel - IP Transactions
Eli Lilly and Company (Indianapolis, IN)
In the year since we last met, there have been numerous developments influencing the life sciences industry, including new lawmaking initiatives, a presidential election, and the COVID-19 pandemic which has created a palpable shift in the way many companies approach business transactions. Our esteemed co-chairs will kick off the event with an exploration of the last year’s most significant developments that are impacting life science company pipelines, reshaping future business analyses and influencing the strategies and decisions made during the IP due diligence process.